Trpc6 Promotes Doxorubicin-Induced Cardiomyopathy in Male Mice With Pleiotropic Differences Between Males and Females

Background: Doxorubicin is a widely used and effective chemotherapy, but the major limiting side effect is cardiomyopathy which in some patients leads to congestive heart failure. Genetic variants in TRPC6 have been associated with the development of doxorubicin-induced cardiotoxicity, suggesting th...

Descripción completa

Detalles Bibliográficos
Autores principales: Norton, Nadine, Bruno, Katelyn A., Di Florio, Damian N., Whelan, Emily R., Hill, Anneliese R., Morales-Lara, Andrea Carolina, Mease, Anna A., Sousou, John M., Malavet, Jose A., Dorn, Lauren E., Salomon, Gary R., Macomb, Logan P., Khatib, Sami, Anastasiadis, Zacharias P., Necela, Brian M., McGuire, Molly M., Giresi, Presley G., Kotha, Archana, Beetler, Danielle J., Weil, Raegan M., Landolfo, Carolyn K., Fairweather, DeLisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792457/
https://www.ncbi.nlm.nih.gov/pubmed/35096991
http://dx.doi.org/10.3389/fcvm.2021.757784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792457/
https://www.ncbi.nlm.nih.gov/pubmed/35096991
http://dx.doi.org/10.3389/fcvm.2021.757784

Ejemplares similares